TU-Eindhoven

October 21, 2023

TU-Eindhoven # cELPro for non-invasive, affordable treatment of IBD # Inflammatory bowel disease is a chronic inflammatory disease of the gastrointestinal tract that affects 4.9 million people worldwide. Current treatments aim at relieving the symptoms of the disease. However, those are not specific enough, cause many side effects or are very expensive. The TU-Eindhoven team wants to tackle this challenge by developing an affordable, safe, targeted microbe-based therapy that works locally in the bowel. ...